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Background: Accumulated evidence from epidemiological studies and more recently from randomized controlled
trials suggests that male circumcision (MC) may substantially protect against genital HPV infection in men. The
purpose of this study was to assess the association between MC and genital HPV infection in men in a large
multinational study.
Methods: A total of 4072 healthy men ages 18–70 years were enrolled in a study conducted in Brazil, Mexico, and
the United States. Enrollment samples combining exfoliated cells from the coronal sulcus, glans penis, shaft, and
scrotum were analyzed for the presence and genotyping of HPV DNA by PCR and linear array methods. Prevalence
ratios (PR) were used to estimate associations between MC and HPV detection adjusting for potential confounders.
Results: MC was not associated with overall prevalence of any HPV, oncogenic HPV types or unclassified HPV types.
However, MC was negatively associated with non-oncogenic HPV infections (PR 0.85, 95% confident interval:
0.76-0.95), in particular for HPV types 11, 40, 61, 71, and 81. HPV 16, 51, 62, and 84 were the most frequently
identified genotypes regardless of MC status.
Conclusions: This study shows no overall association between MC and genital HPV infections in men, except for
certain non-oncogenic HPV types for which a weak association was found. However, the lack of association with
MC might be due to the lack of anatomic site specific HPV data, for example the glans penis, the area expected to
be most likely protected by MC.
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Genital human papillomavirus (HPV) infection is one of
the most common sexually transmitted infections (STI) in
the world [1]. Genital HPV prevalence in men has been
reported to range from 2% to 93% among high-risk men
such as HIV-positive males, male partners of women with
HPV infection or abnormal cytology, and patients atten-
ding STI clinics and from 1% to 84% among all other
groups [2]. Most observational studies have shown an in-
verse association between male circumcision (MC) and
genital HPV infection [3-9]. Three randomized controlled* Correspondence: anna.giuliano@moffitt.org
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reproduction in any medium, provided the ortrials (RCT) in Africa have shown that MC substantially
reduces HIV infection in men [10-12], and two of these
have also found that MC reduced the prevalence of high
risk HPV infections [13,14]. A recent systematic review
and meta-analysis showed an inverse association between
MC and genital HPV prevalence in men [15]. Another
review reported a strong protective effect of MC against
penile cancer [16]. However, the association reported
between MC and genital HPV infection has not been con-
sistent across all studies [17-21]. We previously published
interim data in support of an inverse association between
MC and genital HPV detection in the first 1158 men
enrolled in the HPV in Men study (HIM Study) [6]. In the
present analysis, we re-evaluated the association betweenLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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effect modification by sexual behavior among all men en-
rolled in the HIM Study.
Methods
Study population
The HIM Study is a multinational longitudinal study of
HPV in men. Between June 2005 and September 2009,
4072 men who completed both the pre-enrollment and the
enrollment visits formed the study population for the
present analysis. Details of the cohort have been previously
described [6,22]. In brief, men were eligible for participation
if they were aged 18–70 years, residents of Tampa, Florida,
Cuernavaca, Mexico, or São Paulo, Brazil, had no prior anal
or penile cancer or genital warts, and no current diagnosis
of STIs. Men were recruited from several population
sources. In Brazil, men were recruited from the general
population, public health clinic attendees, and partners of
women participating in a natural history study of HPV.
Men visiting the clinic for STI symptoms or treatment were
excluded. In Mexico, men were recruited through a large
health plan, from factories, and the military. In the United
States, men were recruited from the University of South
Florida and the Tampa metropolitan area. Men who were
eligible to participate reviewed a written informed consent
with a trained study team member. Consenting partici-
pants underwent a clinical examination at 10 visits: a pre-
enrollment visit, an enrollment visit approximately 2 weeks
later, and 8 additional visits after enrollment that occurred
every 6 months over a period of 4 years. Before study ini-
tiation, the human subjects committees of the University of
South Florida, the Centro de Referencia e Tratamento de
Doencas Sexualmente Transmissiveis e AIDS, Brazil, and
the National Institute of Public Health of Mexico approved
the research protocol.
At the enrollment visit, men completed an 88-item Com-
puter-Assisted Self-Interview (CASI) that has been demon-
strated to elicit reliable responses [23]. The CASI collected
information about participant socio-demographic charac-
teristics, tobacco consumption, and sexual behaviors. After
the interview, a clinician examined each participant for
signs of STIs and assessed circumcision status. Participants
with full or partial circumcision were considered to be
circumcised.
Penile and scrotal sampling
Three different saline pre-wetted Dacron (Digene,
Gaithersburg, MD, USA) swabs were obtained from
the coronal sulcus/glans penis, penile shaft, and scro-
tum, and placed in 450 μl of Specimen Transportation
Medium, and combined into one sample before DNA
extraction. Among uncircumcised men, the foreskin
was sampled at the time of collection of the coronal
sulcus/glans penis sample. We have previously shownthe validity and high sampling reproducibility of these
three anatomical sites in the assessment of HPV DNA
status [24,25]. All HPV samples were stored at −80°C
until PCR analysis and genotyping were performed.
HPV analyses
DNA was extracted with the Media Kit (QIAGen, Valencia,
CA, USA) by a robotic system according to the manufac-
turer’s instructions. DNA was stored at 4°C until use. HPV
testing of the combined DNA extract was undertaken by
use of PCR for amplification of a fragment of the HPV L1
gene. Specimens were tested for the presence of HPV by
amplification of 30 ng of DNA with the PGMY09/11 L1
consensus primer system [26]. HPV genotyping was done
with the linear array method on all samples irrespective
of the HPV PCR result (Roche Molecular Diagnostics,
Alameda, CA, USA) [27].
Before genotyping, amplification products were run on
2% agarose gels to visualise a 450 bp band corresponding
to HPV amplification for identification of samples that
might have an HPV type other than the 37 types ana-
lyzed in the genotyping assay. Samples in which HPV
was amplified on PCR, but did not hybridise with a spe-
cific HPV type during genotyping were categorized as
unclassified infections. The 13 HPV types that were clas-
sified as oncogenic were: 16, 18, 31, 33, 35, 39, 45, 51,
52, 56, 58, 59 and 68. The non-oncogenic HPV types
were: 6, 11, 26, 40, 42, 53, 54, 55, 61, 62, 64, 66, 67, 69,
70, 71, 72, 73, 81, 82, 83, 84, IS39, and CP6108 [28].
Samples were considered valid if they were HPV positive
by PCR or by genotyping, or β-globin positive, regardless
of HPV result. Valid samples were available from 3969
of 4072 participants.
Statistical analysis
The present analysis included four classifications of
HPV detection. A participant was considered positive
for “Any HPV type” if he tested HPV positive by PCR or
by genotyping for any HPV genotype. The category of
“Oncogenic HPV” included men who were positive for
only oncogenic genotypes as well as those who were posi-
tive for both oncogenic and non-oncogenic types. The
“Non-oncogenic HPV” category consisted of those partici-
pants who tested positive for non-oncogenic HPV geno-
types only. The “Unclassified HPV infections” included
men with samples that tested positive for HPV by PCR
but negative for all of the 37 genotypes tested.
Differences in the distribution of socio-demographic
characteristics, tobacco consumption and sexual beha-
vior characteristics by circumcision status were com-
pared using Pearson’s chi-square test. Prevalence ratios
(PRs) and 95% confidence intervals (CIs) were estimated
using univariate and multivariable modified Poisson
regression with robust variance [29,30]. Separate models
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oncogenic HPV, non-oncogenic HPV, and unclassified
HPV infections). Uncircumcised men served as the refe-
rence group for circumcision status, and men who had no
detectable HPV (HPV negative on both PCR and geno-
typing assays) served as the comparison group in the
modeling of each HPV outcome. All risk factor variables
and potential confounders were initially considered using
multivariable modified Poisson regression modeling. For
variable selection, all variables in a model were included,
and then individually eliminated if not statistically signifi-
cant at the 0.05 level. This variable selection procedure
was performed for the four HPV outcomes. Variables that
were not statistically significant in any of the models were
excluded from the final multivariable models.
To explore whether sexual behavior modified the asso-
ciation between MC and HPV detection, we stratified the
analysis by lifetime number of female sexual partners, and
formally tested the interaction between lifetime number of
female sexual partners and MC by including in the model
both the interaction and the main-effect terms. Statistical
analyses were conducted using SAS software, version 9.2
(SAS Institute Inc., Cary, NC) and R 2.13.0 (R Develop-
ment Core Team). All statistical tests were two sided with
a significance threshold of 0.05.
Results
Socio-demographic characteristics of the 3969 partici-
pants by circumcision status are summarized in Table 1.
The majority of men were uncircumcised (64.1%). The
mean age of participants was 30.9 years among circum-
cised men and 33.4 years among uncircumcised men.
Most circumcised men were recruited from the United
States (72.1%) and among uncircumcised men, 46.8%
were recruited from Brazil, and 43.8% from Mexico.
Among circumcised men, 66.2% were positive for any
HPV, 29.4% for oncogenic HPV, 19.7% for non-oncogenic
HPV only, and 17.1% for unclassified HPV infections.
Among uncircumcised men, 67.0% were positive for any
HPV, 30.0% for oncogenic HPV, 24.3% for non-oncogenic
HPV, and 12.7% for unclassified HPV infections. Statis-
tically significant differences by circumcision status were
observed for age, country of residence, race, marital status,
education, sexual orientation, number of female sexual
partners in the past 3–6 months, male anal sexual partners
in the past 3 months, self-reported STI history, and HPV
status.
The univariate and multivariable associations of MC
with each of the four pre-defined individual outcomes
(i.e., any HPV, oncogenic HPV, non-oncogenic HPV, and
unclassified HPV infections) are presented in Table 2.
No association was observed between MC and HPV de-
tection for any HPV or oncogenic HPV in either the
univariate or the multivariable analyses. However, MCwas significantly negatively associated with non-oncogenic
HPV detection in both the univariate (PR 0.87, 95% CI
0.78-0.97) and the multivariable models (PR 0.85, 95% CI
0.76-0.95). MC was significantly positively associated with
prevalence of unclassified HPV infections in the univariate
analysis (PR 1.21, 95% CI 1.05-1.39) but not in the final
multivariable analysis (PR 1.07, 95% CI 0.92-1.24).
As shown in Table 3, the association between MC and
non-oncogenic HPV differed significantly by the number
of lifetime female sexual partners (test of interaction,
P = 0.006). Thus, MC was associated with a reduced
prevalence of non-oncogenic HPV infections among
men reporting 1 to 4 lifetime female sexual partners in
both models (univariate PR 0.62, 95% CI 0.45-0.83; mul-
tivariable PR 0.59, 95% CI 0.42-0.83). In contrast, no
association with MC was observed among men reporting
5 or more lifetime female sexual partners for non-
oncogenic HPV. Although in the univariate analysis MC
was associated with a statistically significant increased risk
of unclassified HPV infections (PR 1.24, 95% CI 1.01-1.51)
among men reporting 1–4 partners, the PR was reduced
to 1.03 (95% CI 0.82-1.28) in the final multivariable ana-
lysis. No associations with MC were observed among men
reporting 5 or more lifetime female sexual partners for
any HPV, oncogenic HPV, or unclassified HPV infections.
The test of interaction between MC and lifetime female
sexual partners was not statistically significant for the
other three outcomes (i.e., any HPV type, oncogenic HPV,
and unclassified HPV infections). Moreover, no asso-
ciation was found between MC and detection of HPV by
country of residence (data not shown).
Table 4 presents the type-specific HPV distribution by
circumcision status. HPV 16, 51, 62, 84, and CP6108
were the most frequently identified genotypes regardless
of MC status. Concerning individual HPV genotypes, MC
was associated with significantly reduced risk of non-
oncogenic HPV types 11 (PR 0.46, 95% CI 0.24-0.88), 40
(PR 0.30, 95% CI 0.15-0.61), 61 (PR 0.50, 95% CI 0.36-
0.71), 71 (PR 0.17, 95% CI 0.07-0.43), and 81 (PR 0.55,
95% CI 0.36-0.82). MC was not associated with prevalence
of any of the individual thirteen oncogenic HPV types
detected.
Discussion
Our study found that MC was not associated with over-
all prevalence of genital HPV for any HPV, oncogenic
HPV infections, or unclassified HPV infections. How-
ever, MC was negatively associated with non-oncogenic
HPV infections. After adjustment for potential confoun-
ders and stratification by lifetime number of female
sexual partners, the protective association between MC
and non-oncogenic HPV detection was particularly evi-
dent in men reporting 1 to 4 lifetime female sexual part-
ners. The lack of an effect of MC among men with a
Table 1 Socio-demographic characteristics of study participants by circumcision status N = 3969
Circumcision P-value
No Yes
N = 2545 (64.1%) N = 1424 (35.9%)
N % N %
Age < 0.001
Mean (SD) 33.4 (10.3) 30.9 (12.1)
18-30 1115 43.8 822 57.7
31-44 1119 44.0 406 28.5
45-70 311 12.2 196 13.8
Country of residence < 0.001
US 241 9.5 1027 72.1
Brazil 1190 46.8 197 13.8
Mexico 1114 43.8 200 14.0
Race < 0.001
White 877 35.1 889 63.1
Black 397 15.9 218 15.5
Asian/Pacific Islander 65 2.6 46 3.3
Mexican 1020 40.8 183 13.0
Other (American Indian, Mixed) 141 5.6 73 5.2
Unknown 45 15
Marital status < 0.001
Single 946 37.3 838 58.9
Married 1035 40.8 322 12.7
Cohabiting 373 14.7 104 4.1
Divorced/Separated/Widowed 183 7.2 158 11.1
Unknown 8 2
Education < 0.001
<12 Years 750 29.6 133 9.3
Completed 12 Years 774 30.6 292 20.5
13-15 Years 377 14.9 623 43.8
Completed 16 Years 497 19.6 273 19.2
≥17 Years 135 5.3 102 7.2
Unknown 12 1
Current smoker 0.054
No 1916 75.4 1112 78.2
Yes 624 24.6 310 21.8
Unknown 5 2
Sexual orientation < 0.001
MSW 2092 82.5 1245 87.7
MSWM 161 6.4 54 3.8
MSM 132 5.2 41 2.9
No sex 150 5.9 79 5.6
Unknown 10 5
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Table 1 Socio-demographic characteristics of study participants by circumcision status N = 3969 (Continued)
Lifetime female sexual partners 0.059
Median (SD) 6 (2055.1) 7 (79.4)
0-1 440 18.5 253 18.4
2-9 1040 43.8 560 40.8
10-19 416 17.5 234 17.0
20-49 354 14.9 229 16.7
50+ 124 5.2 98 7.1
Unknown 171 50
Female sexual partners in past 3–6 months < 0.001
Mean (SD) 1.4 (2.4) 1.4 (1.7)
0 717 30.7 329 24.3
1 940 40.3 668 49.3
2 349 15.0 163 12.0
3+ 326 14.0 196 14.5
Unknown 213 68
Male anal sexual partners in past 3 months 0.002
Mean (SD) 0.3 (3.3) 0.1 (1.0)
0 2341 92.9 1363 95.7
1 75 3.0 25 1.8
2 31 1.2 16 1.1
3+ 73 2.9 20 1.4
Unknown 25 0
Diagnosis of STIs, ever < 0.001
No 1992 81.3 1209 86.9
Yes 459 18.7 183 13.1
Unknown 94 32
HPV status < 0.001
Negative 840 33.0 481 33.8
Oncogenic HPV 763 30.0 419 29.4
Non-oncogenic HPV 618 24.3 280 19.7
Unclassified HPV 324 12.7 244 17.1
HPV multiple infections 0.169
2+ HPV types 794 57.5 379 54.2
1 HPV type 587 42.5 320 45.8
Negative 840 481
NOTE. SD, standard deviation; US, the United States; MSW, men who have sex with women; MSWM, men who have sex with women and men; MSM, men who
have sex with men; STI, sexually transmitted infections. Numbers in bold correspond to P values < 0.05.
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explained by immunity to HPV acquired over time by
men who were repeatedly exposed to HPV infections
[6]. Other studies have observed a plateau in risk for
HPV detection despite increasing number of lifetime
sexual partners [3,6]. However, in another analysis of the
HIM Study, anti-HPV 16 serum antibody status at
enrollment was not associated with the risk of a subse-
quent genital HPV 16 infection [31].A preliminary analysis of the HIM study that included
the first 1158 men who completed both the pre-
enrollment and the enrollment visits, showed that MC
was negatively associated with the detection of both
non-oncogenic and oncogenic HPV types [6]. However,
after increasing the sample size to 3969 men in this ana-
lysis, the association was only found for non-oncogenic
HPV types after adjusting for potential confounders.
Three other studies have reported statistically significant
Table 2 Association between male circumcision and genital HPV detection in men
Any HPV
(n = 3969)
Oncogenic HPV
(n = 2503)
Non-Oncogenic HPV
(n = 2219)
Unclassified HPV
(n = 1889)
Univariate Multivariable1 Univariate Multivariable1 Univariate Multivariable1 Univariate Multivariable1
PR (95% CI) PR (95% CI) PR (95% CI) PR (95% CI) PR (95% CI) PR (95% CI) PR (95% CI) PR (95% CI)
Circumcision
No 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0
Yes 0.99 (0.94 - 1.04) 0.96 (0.91 - 1.01) 0.98 (0.90 - 1.07) 0.95 (0.87 - 1.03) 0.87 (0.78 - 0.97) 0.85 (0.76 - 0.95) 1.21 (1.05 – 1.39) 1.07 (0.92 – 1.24)
NOTE. PR, prevalence ratio; CI, confidence interval. Numbers in bold correspond to statistically significant point estimates.
1Adjusted for race, marital status, lifetime female sexual partners, female sexual partners in past 3–6 months and male anal sexual partners in the past 3 months.
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HPV types [5,14,32]. One MC RCT conducted in South
Africa observed significantly lower prevalence of both
oncogenic and non-oncogenic HPV types in urethral swab
samples among circumcised men than uncircumcised
men [13,32]. In another clinical trial in Uganda, the preva-
lence of both oncogenic and non-oncogenic HPV types
using samples of the coronal sulcus/glans penis was lower
among circumcised men than uncircumcised men [14].
Further, a study conducted among men attending a publicTable 3 Association between MC and genital HPV detection i
N
Any HPV
Lifetime number of female partners
1-4 1099
5-12 1183
13+ 1083
Oncogenic HPV
Lifetime number of female partners
1-4 667
5-12 726
13+ 697
Non-Oncogenic HPV
Lifetime number of female partners
1-4 647
5-12 668
13+ 542
Unclassified HPV
Lifetime number of female partners
1-4 717
5-12 527
13+ 330
NOTE. PR, prevalence ratio; CI, confidence interval. Numbers in bold correspond to
1Adjusted for race, marital status, female sexual partners in past 3–6 months and m
2Test for interaction between MC and lifetime number of female partners.
3Adjusted for race, marital status, and male anal sexual partners in the past 3 montSTI clinic, found that MC was associated with reduced
risk for both oncogenic and non-oncogenic HPV types
using samples of the coronal sulcus/glans penis [5]. How-
ever, results from three other studies did not support a
protective role of MC on genital non-oncogenic HPV in-
fection [3,19,20].
The study of the effects of MC on genital HPV infections
poses inherent complexities. Inconsistency of results across
studies may be due to the genital site selected for HPV
sampling or by the procedure used to collect exfoliatedn men by lifetime number of female partners
Circumcision
No Yes
Univariate Multivariable1
PR (95% CI) PR (95% CI)
P = 0.1462
1.00 0.97 (0.87-1.08) 0.92 (0.81-1.03)
1.00 0.98 (0.91-1.07) 0.96 (0.88-1.05)
1.00 1.03 (0.97-1.10) 1.03 (0.96-1.10)
P = 0.2042
1.00 0.93 (0.73 - 1.19) 0.96 (0.73 - 1.26)
1.00 0.96 (0.82 - 1.12) 0.92 (0.77 - 1.09)
1.00 1.06 (0.95 - 1.18) 1.06 (0.95 - 1.19)
P = 0.0062
1.00 0.62 (0.45 - 0.83) 0.59 (0.42 - 0.83)
1.00 0.89 (0.74 - 1.07) 0.88 (0.72 - 1.08)
1.00 1.03 (0.88 - 1.20) 1.03 (0.88 - 1.21)
P = 0.9522
1.00 1.24 (1.01 – 1.51) 1.03 (0.82 – 1.28)3
1.00 1.25 (0.96 – 1.61) 1.15 (0.86 – 1.53)3
1.00 1.19 (0.83 – 1.71) 1.10 (0.74 – 1.62)3
statistically significant point estimates.
ale anal sexual partners in the past 3 months.
hs.
Table 4 Genital type-specific HPV distribution in men by
circumcision status
HPV Circumcision N
total
PR (95% CI)
No Yes
N % N %
Oncogenic
16 190 7.5 117 8.2 307 1.10 (0.88-1.37)
18 51 2.0 40 2.8 91 1.40 (0.93-2.11)
31 51 2.0 20 1.4 71 0.70 (0.42-1.17)
33 20 0.8 4 0.3 24 0.36 (0.12-1.04)
35 41 1.6 24 1.7 65 1.05 (0.63-1.72)
39 96 3.8 49 3.4 145 0.91 (0.65-1.28)
45 47 1.8 18 1.3 65 0.68 (0.40-1.17)
51 158 6.2 95 6.7 253 1.07 (0.84-1.37)
52 166 6.5 78 5.5 244 0.84 (0.65-1.09)
56 55 2.2 20 1.4 75 0.65 (0.39-1.08)
58 71 2.8 27 1.9 98 0.68 (0.44-1.05)
59 131 5.1 91 6.4 222 1.24 (0.96-1.61)
68 54 2.1 37 2.6 91 1.22 (0.81-1.85)
Non-oncogenic
6 156 6.1 84 5.9 240 0.96 (0.74-1.24)
11 43 1.7 11 0.8 54 0.46 (0.24-0.88)
26 4 0.2 4 0.3 8 1.79 (0.45-7.14)
40 54 2.1 9 0.6 63 0.30 (0.15-0.60)
42 40 1.6 15 1.1 55 0.67 (0.37-1.21)
53 141 5.5 86 6.0 227 1.09 (0.84-1.41)
54 56 2.2 34 2.4 90 1.09 (0.71-1.65)
55 64 2.5 35 2.5 99 0.98 (0.65-1.47)
61 147 5.8 39 2.7 186 0.47 (0.34-0.67)
62 218 8.6 102 7.2 320 0.84 (0.67-1.05)
64 3 0.1 1 0.1 4 0.60 (0.06-5.72)
66 124 4.9 81 5.7 205 1.17 (0.89-1.53)
67 16 0.6 4 0.3 20 0.45 (0.15-1.33)
69 7 0.3 1 0.1 8 0.26 (0.03-2.07)
70 71 2.8 29 2.0 100 0.73 (0.48-1.12)
71 53 2.1 5 0.4 58 0.17 (0.07-0.42)
72 39 1.5 12 0.8 51 0.55 (0.29-1.05)
73 51 2.0 22 1.5 73 0.77 (0.47-1.27)
81 94 3.7 28 2.0 122 0.53 (0.35-0.81)
82 18 0.7 12 0.8 30 1.19 (0.58-2.47)
83 81 3.2 31 2.2 112 0.68 (0.45-1.03)
84 197 7.7 119 8.4 316 1.08 (0.87-1.34)
IS39 20 0.8 6 0.4 26 0.54 (0.22-1.33)
CP6108 162 6.4 113 7.9 275 1.25 (0.99-1.57)
NOTE. PR, prevalence ratio; CI, confidence interval. Numbers in bold
correspond to statistically significant point estimates.
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a pooled combination of a few sites for the detection of
HPV. It has been suggested that sampling of the penile
shaft, the coronal sulcus/glans penis, and the scrotum is
necessary for optimal overall genital HPV detection [25]. In
a US study, an inverse association was found between MC
and HPV detection in samples from the urethra, coronal
sulcus/glans penis, and penile shaft, but not in samples
from the scrotum, semen, anal canal, and perianal area
[33]. In another US study, the inverse association between
MC and HPV detection was restricted to the coronal
sulcus/glans penis [20]. A recently published longitudinal
study conducted in the US among 477 male university stu-
dents, uncircumcised men were also more likely to have
HPV-positive glans and urine specimens than circumcised
men, whereas circumcised men were more likely to be
positive in the shaft/scrotum [34].
Taken together, results from these studies consistently
show that the protective effect of MC may be restricted
to infections occurring at the distal part of the penis, in-
cluding the urethra, the coronal sulcus, and the glans.
Since MC is limited to the removal of the foreskin, it
seems unlikely that MC has any effect on infections
occurring in the rest of the penis or the scrotum. Indeed
the use in our study of an aggregate outcome that com-
bined infections in more than one anatomical site greatly
limited our ability to identify a true protective effect in
specific anatomical subsites, possibly resulting in an
overall underestimation of a MC protective effect.
It is interesting to note that this anatomical site-
specific pattern of HPV infections is also observed for
genital warts in at least two clinical studies [35,36]. One
study of men attending an STD clinic in England found
that circumcised men presented genital warts more
often on the shaft of the penis and less often on the
glans penis than uncircumcised men [35]. Similarly, in a
study of heterosexual men attending an STD clinic in
Washington, circumcised men presented genital warts
more often on the penile shaft whereas uncircumcised
men presented genital warts more often on the glans,
corona, frenulum or meatus [36]. It is clear from these
clinical studies that MC differentially reduces the risk of
genital warts in the glans as compared to the rest of the
genital area. As approximately 90% of genital warts are
related to HPV 6/11 infections [37], these data are con-
sistent with our finding that MC is associated with a sig-
nificantly reduced prevalence of HPV 11.
It is unclear why MC would be associated with a
reduced detection of non-oncogenic HPV types but not
of oncogenic HPV types. One possible explanation is
that MC infers a weak protective effect capable of pre-
venting only less virulent HPV infections such as those
caused by non-oncogenic types. Indeed, some studies
provide evidence that non-oncogenic HPV types have a
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However, our own previous data from the HIM Study
showed that the median time to clearance was not
substantially different between non-oncogenic and
oncogenic HPV types [40].
In this study, the distribution of the most common
HPV types was not different by MC status. However, for
less common types, such as HPV types 11, 40, 61, 71
and 81, we did find a lower prevalence in circumcised
men than in uncircumcised men. Four studies have
reported on the type-specific HPV distribution by MC
status [20,32,34,41]. In a clinical trial of MC among
young men in South Africa, HPV types 40, 42, 53, 70,
84, and CP6108 were found in the intention-to-treat
analysis to be less frequently detected in circumcised
men as compared to uncircumcised men when using
urethral samples [32]. In another study of university
males in Hawaii, the distribution of non-oncogenic HPV
types in the coronal sulcus/glans penis did not vary by
circumcision status, HPV 84 being the most common
non-oncogenic type in both circumcised and uncircum-
cised men. However, the distribution of oncogenic HPV
types did vary by MC status. Thus, while the most com-
mon oncogenic HPV types among circumcised men
were types 16 and 39, those among uncircumcised men
were types 66, 52, 53, and 73 [20]. Consistent with these
two studies on type-specific prevalence, an RCT in
Uganda found that type-specific incidence rates of HPV
types 18 and 33 were lower in circumcised men than in
uncircumcised men. Similarly, type-specific clearance
rates for HPV types 39, 51, and 58 over a 24-month
period were increased in circumcised men as compared
to uncircumcised men when using samples from the
coronal sulcus/glans penis [41]. Finally, in a longitudinal
study of university males in Washington using samples
from the penile shaft/scrotum, corona sulcus/glans, and
urine, the incidence of the most common HPV types
did not vary by circumcision status. The most common
oncogenic HPV types at the 36-month cumulative
incidence were 16, 18, and 51, and the most common
non-oncogenic HPV types were 6, 53, and 66 in both
circumcised and uncircumcised men [34].
The mechanism by which circumcision might protect
against HPV infection remains unclear. Removal of the
foreskin could minimize the chance of acquisition of
new infections or could result in an increased clearance
of preexisting infections [4,42]. Additional data on HPV
acquisition and clearance according to MC status and
anatomical site are necessary to better assess the role of
MC in the natural history of HPV infections in men.
Conclusions
In conclusion, this study shows no association between
MC and an overall prevalence of genital HPV infectionsin men but MC is associated with a reduced prevalence
of genital non-oncogenic HPV types. However, the lack
of association with MC might be due to the analysis
could not asses specific associations in the glans penis,
the area expected to be most likely protected by removal
of the foreskin.
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